The Hemophilia Foundation of Southern California (HFSC) has named hematologist-oncologist Akshat Jain as the 2025 Medical Provider of the Year.
The award recognizes his “outstanding dedication, compassion, and commitment to the care of individuals and families living with bleeding disorders,” HFSC noted in a statement.
Also read: NYC Mayor honors Indian American surgeon Raj Bhayani
Accepting the award, Jain said, “This recognition is a reflection of the courageous individuals and families living with bleeding disorders whom I have the privilege to serve. Their strength inspires every step of this journey.”
He also acknowledged the vital role of his dedicated team, stating, “I share this award with my exceptional team, who remain committed to delivering compassionate, comprehensive, and equitable care for all.”
An assistant professor of pediatrics, hematology/oncology division at Loma Linda University School of Medicine, Jain has led groundbreaking clinical trials and research in gene therapy, aiming to transform outcomes for patients with rare blood disorders.
Over the past seven years, he has built a thriving clinical and research program, and now envisions creating a comprehensive center of excellence in hematology and gene therapy for the Inland Empire.
Jain has been honored with numerous awards for his contributions to pediatric healthcare. His expertise in classic hematology and global health has earned him key roles on national and international medical committees.
As a consultant to Ministries of Health across several countries and an advisor to the World Health Organization, he plays a vital role in shaping healthcare strategies for rare blood disorders. In 2024, he was appointed as the Ambassador for the American Society of Hematology.
The honor was presented during HFSC’s annual recognition ceremony in Pasadena. Executive director Rigoberto Garcia praised Jain’s unwavering advocacy and compassionate service to the bleeding disorders community.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login